tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Laekna, Inc. Reports Positive Phase I Results for Obesity Treatment

Story Highlights
Laekna, Inc. Reports Positive Phase I Results for Obesity Treatment

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Laekna, Inc. ( (HK:2105) ) has issued an announcement.

Laekna, Inc. announced positive preliminary results from their Phase I multiple ascending dose study of LAE102, aimed at treating obesity. The study showed promising trends in increasing lean body mass and reducing fat mass among participants, with a well-tolerated safety profile and no serious adverse events. These results support further clinical development and potential partnerships to accelerate the commercialization of LAE102, positioning it as a promising candidate for effective weight control.

The most recent analyst rating on (HK:2105) stock is a Buy with a HK$26.45 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.

More about Laekna, Inc.

Laekna, Inc. is a biotechnology company focused on the development of innovative therapies, particularly in the field of obesity treatment. The company is engaged in the clinical development of LAE102, a monoclonal antibody targeting ActRIIA, which plays a significant role in muscle regeneration and lipid metabolism.

Average Trading Volume: 4,349,127

Technical Sentiment Signal: Buy

For an in-depth examination of 2105 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1